Thromb Haemost 2000; 83(06): 840-843
DOI: 10.1055/s-0037-1613930
Commentary
Schattauer GmbH

Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia Treated with Delayed E. coli Asparaginase (COALL-92 and 97 Protocols)

Christine Mauz-Körholz
1   From the Department of Paediatric Haematology and Oncology, Heinrich-Heine University Medical Centre Düsseldorf
,
Ralf Junker
3   Department of Clinical Chemistry and Laboratory Medicine/Institute of Arteriosclerosis Research, Westfälische-Wilhelms-University Medical Centre, Münster, Germany
,
Ulrich Göbel
1   From the Department of Paediatric Haematology and Oncology, Heinrich-Heine University Medical Centre Düsseldorf
,
Ulrike Nowak-Göttl
2   Department of Paediatric Haematology and Oncology
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 01. Oktober 1999

Accepted after resubmission 20. Januar 2000

Publikationsdatum:
14. Dezember 2017 (online)

Zoom Image

Summary

Hereditary prothrombotic risk factors have been shown to increase the risk of venous thrombosis in children treated with the combination of E. coli asparaginase and steroids. In the present study the role of prothrombotic risk factors in children with ALL treated according to the COALL study protocol was investigated in 108 consecutively recruited childhood patients. The prevalence rates of prothrombotic risk factors [factor V G1691A mutation, the prothrombin G20210A variant, the TT677 methylenetetrahydrofolate reductase genotype, deficiencies of protein C, protein S, antithrombin, elevated lipoprotein (a)] in this cohort were within the range reported for healthy Caucasians, and comparable to previously reported data for other leukemic patients. Venous thromboembolism occurred in 3 of the 108 children (induction n = 1; reinduction n = 2: 2.8%), and none of these children carried a prothrombotic risk factor. The results of the present study, suggest that the role of hereditary and acquired disturbances of coagulation in the development of thromboses might depend on the treatment regimen.